Softwr

Healthcare · head to head

Annalise.ai vs Epocrates

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Epocrates logo

Epocrates

Healthcare

Mobile clinical reference and decision support app

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Epocrates has a free tier, so it costs nothing to try first.
  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Epocrates pricing page not publicly accessible
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Epocrates covers Drug Reference.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Epocrates actually diverge.

Attributes where Annalise.ai and Epocrates differ
AttributeAnnalise.aiEpocrates
Starting priceOn requestFree
Pricing modelquotefreemium
Free tierNoYes
PlatformsWeb, Cloud, On-premiseMobile
FoundedUnknown2000

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Epocrates

  • Drug Reference
  • Interactions
  • Dosing Calculators
  • Disease Information
  • Medical Procedures
  • Patient Education
  • EHR Systems
  • HIPAA

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Epocrates
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Epocrates
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Epocrates
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Epocrates

Epocrates

  • Patient Carenot Annalise.ai
  • Medical Recordsnot Annalise.ai
  • Practice Managementnot Annalise.ai
  • Telehealthnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Epocrates

  • Pricing page not publicly accessible

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Epocrates

Free
  • FreeFree
    • Drug references
    • Calculators
    • Interactions
  • Premium$99/year
    • Enhanced content
    • Offline access

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Epocrates if

  • You need drug reference.
  • You want to start without paying.
  • You work on Mobile.
  • You also want interactions.
Epocrates review

Questions people ask

Is Annalise.ai or Epocrates better?
Neither clearly leads. Annalise.ai starts at On request and Epocrates at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Epocrates?
Epocrates has a free tier; the other does not. Paid plans start at On request for Annalise.ai and Free for Epocrates.
Does Annalise.ai or Epocrates run on more platforms?
Annalise.ai runs on Web, Cloud, On-premise. Epocrates runs on Mobile.
Can I use Epocrates for free?
Yes. Epocrates has a free tier, so you can try it without paying. Annalise.ai starts at On request.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Epocrates is typically brought in for.
What can Annalise.ai do that Epocrates cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Epocrates covers Drug Reference, Interactions, Dosing Calculators, Disease Information.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Epocrates: How much does Epocrates cost?

Epocrates pricing information is not available to public access. Users must authenticate or contact the vendor to view pricing details.

Source
Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Share

Related pages

More on Annalise.ai

More on Epocrates

Keep looking

Other head to heads